(HealthDay)—The U.S. Food and Drug Administration has announced the approval of Dovato (dolutegravir and lamivudine), the first approved two-drug, fixed-dose, complete regimen for adults with HIV-1 who have not been previously ...
Apr 9, 2019
0
0
Although a woman's use of the HIV drug dolutegravir at conception may increase the risk of often-fatal neural tube defects in her child, a new study suggests that the risk may be offset by the drug's ability to decrease deaths ...
Apr 1, 2019
0
22
(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...
Mar 12, 2019
0
2
The latest World Health Organization (WHO) recommendations published in July 2018 advocate first-line treatment of HIV infection using dolutegravir (DTG) as an alternative to treatment with efavirenz at 400 mg (EFV400). Until ...
Nov 1, 2018
0
0
Scientists reported setbacks Tuesday in the quest for an AIDS cure, and highlighted concerns about inconclusive evidence linking a promising new HIV drug to birth defects.
Jul 24, 2018
0
8
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit ...
May 21, 2014
0
0
